Octreotide for Cancer of the Liver and Biliary Tree
暂无分享,去创建一个
[1] K. Toriyama,et al. A clinicpathological study of hepatocellular carcinoma in Nagasaki, south-western Japan: the association of hepatitis B and C viruses. , 1994, The Southeast Asian journal of tropical medicine and public health.
[2] T. Maekawa,et al. [Clinicopathological effects of US-guided intratumoral ethanol injection to small liver cancer with special references to its adequate injected volume]. , 1988, Nihon Gan Chiryo Gakkai shi.
[3] M. Catani,et al. [VIPoma: surgical treatment]. , 1992, Minerva Chirurgica.
[4] M. Colombo,et al. Epidemiology of hepatocellular carcinoma. , 1995, The Italian journal of gastroenterology.
[5] 신동훈,et al. 성인에서 발생한 Hepatoblastoma , 1999 .
[6] G. Liapakis,et al. Molecular and Functional Properties of Somatostatin Receptor Subtypes , 1996 .
[7] S. Kaneko,et al. Clinical Pilot Study of Intrahepatic Arterial Chemotherapy with Methotrexate, 5-Fluorouracil, Cisplatin and Subcutaneous Interferon-Alpha-2b for Patients with Locally Advanced Hepatocellular Carcinoma , 1997, Oncology.
[8] F. Frizelle. Octreotide inhibits the growth and development of three types of experimental liver metastasis , 1995, The British journal of surgery.
[9] J. Belamarić,et al. Intrahepatic bile duct carcinoma and C. sinensis infection in Hong Kong , 1973, Cancer.
[10] R. Warner,et al. An 18-year follow-up of primary hepatic carcinoid with carcinoid syndrome. , 1996, Journal of clinical gastroenterology.
[11] A. Schally,et al. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[12] M. Zins,et al. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. , 1996, European journal of gastroenterology & hepatology.
[13] M. Lobrano,et al. Metastatic carcinoid tumor imaged with CT and a radiolabeled somatostatin analog: a case report. , 1997, The American journal of gastroenterology.
[14] J. Ramage,et al. Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan). , 1996, QJM : monthly journal of the Association of Physicians.
[15] H. Kynaston,et al. Octreotide inhibits the growth and development of three types of experimental liver metastases , 1995, The British journal of surgery.
[16] E. Shalaby-Rana,et al. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome. , 1997, Clinical nuclear medicine.
[17] G. Grazi,et al. Surgical treatment of hepatocellular carcinoma on cirrhosis: a Western experience. , 1998, Hepato-gastroenterology.
[18] G. D'Haens,et al. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. , 1993, The American journal of gastroenterology.
[19] D. Parkin,et al. Liver cancer in Thailand: Temporal and geographic variations , 1988 .
[20] N. Okazaki,et al. Prognosis of Primary Hepatocellular Carcinoma , 1984, Hepatology.
[21] P. Rougier,et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] N. Vaysse,et al. The Tyrosine Phosphatase SHP-1 Associates with the sst2 Somatostatin Receptor and Is an Essential Component of sst2-mediated Inhibitory Growth Signaling* , 1997, The Journal of Biological Chemistry.
[23] D. Hoyer,et al. Binding properties of somatostatin receptor subtypes. , 1996, Metabolism: clinical and experimental.
[24] T. Livraghi,et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. , 1995, Radiology.
[25] H. Kynaston,et al. Effects of octreotide on liver regeneration and tumour growth in the regenerating liver , 1997, Journal of gastroenterology and hepatology.
[26] Kunio Okuda,et al. Primary liver cancers in Japan , 1980, Cancer.
[27] H. Kynaston,et al. Octreotide, the reticuloendothelial system, and experimental liver tumour. , 1995, Gut.
[28] G. Haddock,et al. Metastatic vipoma arising from colonic primary tumour. , 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[29] Michiie Sakamoto,et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection , 1996, Cancer.
[30] J. Roberts. Carcinoma of the extrahepatic bile ducts. , 1986, The Surgical clinics of North America.
[31] G. Bell,et al. Molecular biology of somatostatin receptors , 1993, Trends in Neurosciences.
[32] W. Scheithauer,et al. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide , 1999, American Journal of Gastroenterology.
[33] I B Anderson,et al. Increase in incidence of disease due to diagnostic drift: primary liver cancer in Denmark, 1943-85. , 1991, BMJ.
[34] A. Vinik,et al. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation. , 1990, Radiology.
[35] A. Flückiger,et al. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide]. , 1992, Schweizerische medizinische Wochenschrift.
[36] A. Bockisch,et al. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases]. , 1997, Langenbecks Archiv fur Chirurgie.
[37] S. Khakoo,et al. HCV-associated hepatocellular carcinoma without cirrhosis. , 1996, Journal of hepatology.
[38] R. Arnold,et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. , 1996, Gut.
[39] G. Kéri,et al. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232 , 1999, British Journal of Cancer.
[40] G. Braunstein,et al. Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. , 1992, Endocrinology.
[41] G. Bell,et al. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. , 1993, Molecular pharmacology.
[42] G. Dusheiko,et al. Epirubicin‐lipiodol chemotherapy versus 131iodine‐lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma , 1995, Cancer.
[43] J. Whang‐Peng,et al. Phase II study of flutamide in the treatment of hepatocellular carcinoma , 1996, Cancer.
[44] R. Danieli,et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] D. Venzon,et al. Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study , 1996, Annals of Internal Medicine.
[46] H. Deguchi,et al. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. , 1994, Internal medicine.
[47] H. Kynaston,et al. Reticuloendothelial stimulation: Levamisole compared , 1993, Diseases of the colon and rectum.
[48] C. Bartolozzi,et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 western patients , 1995, Cancer.
[49] D. Le Guludec,et al. Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). , 1997, Gut.
[50] M. Tzardi,et al. Natural history of advanced hepatocellular carcinoma in Crete. Association with hepatitis C virus , 1997, European journal of gastroenterology & hepatology.
[51] A. Harris,et al. LONG‐TERM TREATMENT OF METASTATIC MEDULLARY THYROID CARCINOMA WITH THE SOMATOSTATIN ANALOGUE OCTREOTIDE , 1990, Clinical endocrinology.
[52] C. B. Srikant,et al. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). , 1994, Endocrinology.
[53] D. Hemingway,et al. The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases. , 1992, British Journal of Cancer.
[54] U. Tylén,et al. Survival of Patients with Disseminated Midgut Carcinoid Tumors after Aggressive Tumor Reduction , 1996, World Journal of Surgery.
[55] E. Wilander,et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. , 1997, Acta oncologica.
[56] D. Bartlett,et al. Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia. , 1995, Surgery.
[57] G. Colucci,et al. 5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.). , 1999, Anticancer research.
[58] H. Iishi,et al. Inhibition by somatostatin of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. , 1993, Carcinogenesis.
[59] J. Grosfeld,et al. Hepatic resection enhances growth of residual intrahepatic and subcutaneous hepatoma, which is inhibited by octreotide. , 1997, Journal of pediatric surgery.
[60] M. Sibony,et al. Adrenocorticotropin-producing pituitary carcinoma with liver metastasis , 1997, Journal of endocrinological investigation.
[61] E. Baudin,et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[62] S. Beningfield,et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. , 1993, Gut.
[63] E. Woltering,et al. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. , 1995, American journal of surgery.
[64] R. Wiesner,et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. , 1991, Annals of Surgery.
[65] S. Hadziyannis,et al. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial , 1995, Hepatology.
[66] C. B. Srikant,et al. Molecular biology of somatostatin receptor subtypes. , 1996, Metabolism: clinical and experimental.
[67] A Morabito,et al. Percutaneous etharrol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients , 1992, Cancer.
[68] M. Kipper,et al. Gallbladder visualization at twenty-four hours with octreotide scintigraphy. Potential false-positive finding. , 1997, Clinical nuclear medicine.
[69] J. Zucker,et al. Could somatostatin scintigraphy be superior to MIBG scan in the staging of stage IVs neuroblastoma (Pepper's syndrome)? , 1996, Clinical nuclear medicine.
[70] L. Kvols. Therapy of the malignant carcinoid syndrome. , 1989, Endocrinology and metabolism clinics of North America.
[71] M. Rothmund,et al. Value of Somatostatin Receptor Scintigraphy for Preoperative Localization of Carcinoids , 1996, World Journal of Surgery.
[72] W. Scheithauer,et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. , 2000, International journal of oncology.
[73] A. Terano,et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. , 1993, AJR. American journal of roentgenology.
[74] T. Livraghi,et al. Liver metastases: results of percutaneous ethanol injection in 14 patients. , 1991, Radiology.
[75] K. Ito,et al. The usefulness of radiation therapy for hepatocellular carcinoma. , 1998, Hepato-gastroenterology.
[76] U. Tylén,et al. Treatment of Liver Metastases of Carcinoid Tumors , 1996, World Journal of Surgery.
[77] T. Livraghi,et al. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. , 1986, Radiology.
[78] G. Nisand,et al. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. , 1996, Journal of hepatology.
[79] L. Mariani,et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group , 1996, Cancer.
[80] E. Kouroumalis,et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study , 1998, Gut.
[81] T. Seki,et al. Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma. , 1989, The American journal of gastroenterology.